CATALYST PHARMACEUTICALS, INC. 4

CFO Michael Wayne Kalb had 13,665 Catalyst Pharmaceuticals common shares, multiple stock options, and RSUs cashed out or cancelled for cash at the $31.50-per-share merger price in connection with the acquisition by Angelini Pharma.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. Chief Financial Officer Michael Wayne Kalb disposed of his equity incentives in connection with the cash acquisition of the company by Angelini Pharma S.p.A. At a merger cash price of $31.50 per share, his 13,665 shares of common stock were cashed out for approximately $430,448. In addition, all reported stock options to purchase common stock with exercise prices of $16.81, $21.12, $22.77, and $31.50 per share and all reported restricted stock units were cancelled at closing and converted into the right to receive cash based on the merger price, with each award vesting in full as a result of the transaction. Post-merger, these Form 4 entries reflect a transactional cleanup of equity awards rather than open-market trading, and Mr. Kalb no longer holds Catalyst equity securities.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000178

Alert Tier

6